Synaptic vesicles undergo a coordinated cycle of trafficking, docking, priming, fusion, release, and recycling to sustain neurotransmission. This cycle involves over 100 coordinated in tightly regulated steps. In neurodegeneration, multiple points in this cycle become impaired, leading to synaptic dysfunction and ultimately neuronal death[@sudhof2004][@bellen2006].
The synaptic vesicle cycle is fundamental to neuronal communication. Each synaptic vesicle must be loaded with neurotransmitters, transported to the active zone, undergo molecular priming steps, fuse with the presynaptic membrane in response to calcium influx, release its contents, and then be recycled through endocytosis for reuse. This process consumes substantial ATP and requires precise protein-protein interactions that are vulnerable to disruption by pathological implicated in neurodegenerative [@de2008][@rizzoli2014].
Synaptic vesicles are generated primarily from the Golgi apparatus through a process involving multiple sorting and trafficking steps. Newly synthesized vesicles must be transported from the soma to synaptic terminals along microtubules, a journey that can span several meters in long projection neurons. Kinesin motors mediate anterograde transport, while dynein motors mediate retrograde transport. In neurodegenerative , mutations in transport and disruption of microtubule integrity impair this essential trafficking[@goldstein2008][@hirokawa2010].
Synapsins are a family of phospho that anchor synaptic vesicles to the cytoskeleton in the reserve pool. Phosphorylation by calcium/calmodulin-dependent protein kinase (CaMK) and protein kinase A (PKA) releases vesicles for mobilization during sustained or high-frequency stimulation. Synapsin dysfunction has been implicated in epilepsy and may contribute to synaptic vulnerability in AD[@gitler2004][@cesenza2012].
Vesicle docking at the active zone involves the formation of a complex of including the SNARE (syntaxin-1, SNAP-25, synaptobrevin/VAMP), Munc13, Munc18, RIM, and ELKS. These form a physical bridge between the vesicle and the presynaptic membrane. Priming converts docked vesicles into a fusion-competent state that can undergo rapid calcium-triggered fusion[@rosenmund1996][@sollner1993].
The Munc13 family of plays a critical role in priming by facilitating the assembly of SNARE complexes. Munc13-1 is essential for synaptic vesicle priming, and its dysfunction can lead to severe neurological deficits. In neurodegenerative , Munc13 activity may be compromised by oxidative modifications or pathological protein interactions[@augustin1999][@richmond2001].
Complexins are small that bind to SNARE complexes and regulate fusion competency. They act as clamps that prevent premature fusion while allowing calcium-triggered fusion to proceed rapidly upon synaptobrevin engagement. The balance between complexin function and synaptotagmin determines the kinetics of neurotransmitter release[@mcmahon1995][@rizo2008].
Synaptotagmin-1 is the primary calcium sensor for triggered fusion. When calcium binds to synaptotagmin's C2 domains, it triggers a conformational change that displaces complexin and promotes SNARE-mediated membrane fusion. The speed of fusion (sub-millisecond) is critical for precise temporal coding in neural circuits[@brose1992][@fernandezchacon2001].
Different synaptotagmin isoforms have different calcium affinities and may be specialized for different types of release. Synaptotagmin-1 and synaptotagmin-2 are involved in fast synchronous release, while synaptotagmin-7 may contribute to asynchronous release. The loss of specific synaptotagmin isoforms in aging or disease could alter release properties and contribute to network dysfunction[@jackman2016][@lin2021].
After fusion, synaptic vesicle components must be retrieved through clathrin-mediated endocytosis or ultrafast endocytosis pathways. The retrieved vesicles must be re-acidified by V-ATPase and reloaded with neurotransmitters by specific transporters. This recycling process typically takes 10-15 seconds and is essential for sustaining neurotransmission under periods of high activity[@heerssen2008][@wu2014].
Dynamin is a GTPase that mediates the final scission of clathrin-coated vesicles from the plasma membrane. Mutations in dynamin-1 have been associated with epileptic encephalopathy, highlighting the importance of proper endocytosis for neurological function. In neurodegenerative , dynamin function may be impaired by oxidative stress or pathological protein modifications[@dittman2009][@ferguson2012].
Nerve terminals maintain distinct synaptic vesicle pools that are functionally specialized:
The size and dynamics of these pools are tightly regulated, and alterations in pool properties are early indicators of synaptic dysfunction in neurodegenerative [@rizzoli2005][@denker2010].
In Alzheimer's disease, synaptic loss is the strongest correlate of cognitive decline. Amyloid-beta (Aβ) oligomers directly impair multiple steps in the synaptic vesicle cycle. Aβ oligomers bind to presynaptic terminals and reduce the number of release-ready vesicles, impair vesicle docking, and decrease the frequency of miniature excitatory postsynaptic currents (mEPSCs)[@selkoe2008][@shelat2009].
Presynaptic deficits in AD: Studies using electrophysiology and imaging have revealed specific presynaptic abnormalities in AD. Synaptophysin and synapsin levels are reduced in AD brain tissue. The number of synaptic vesicles per terminal is decreased, and vesicle cycling kinetics are slowed. These changes occur early in disease progression and may underlie the initial cognitive deficits[@masliah1994][@counts2010].
Tau pathology at synapses: While tau is primarily a microtubule-associated protein, it also localizes to synapses where it may interact with synaptic . Pathological tau species can disrupt synaptic function by impairing vesicle transport, altering neurotransmitter release, and interfering with synaptic protein trafficking. In tau transgenic mice, synaptic deficits precede overt neurodegeneration[@ittner2010][@liu2021].
In Parkinson's disease, synaptic dysfunction occurs early and may precede dopaminergic cell loss. Alpha-synuclein, the primary protein aggregated in PD, is highly enriched at presynaptic terminals where it regulates vesicle trafficking and dopamine release. Wild-type α-synuclein promotes vesicle clustering and may function as a chaperone for SNARE complex assembly. Mutant or aggregated α-synuclein disrupts these functions[@cabin2005][@cheng2011].
Dopaminergic terminal vulnerability: Dopaminergic neurons in the substantia nigra pars compacta have particularly high basal activity and energy demands, making their synaptic terminals especially vulnerable to insults. The unique physiology of dopaminergic terminals, including asynchronous release and pacemaking, may contribute to their selective vulnerability in PD[@sulzer2016][@zhang2017].
Alpha-synuclein and synaptic vesicles: α-Synuclein binds to synaptic vesicles through its N-terminal domain, promoting vesicle clustering and preventing dispersion. In PD, pathological α-synuclein forms oligomers and aggregates that impair normal vesicle function. These aggregates can sequester normal α-synuclein in a prion-like manner, propagating pathology across synaptic connections[@bendor2013][@spillantini1997].
In ALS, synaptic dysfunction affects both excitatory and inhibitory motor neuron synapses. Mutations in multiple ALS-associated genes (SOD1, TDP-43, FUS, C9orf72) cause synaptic deficits. TDP-43 aggregation in presynaptic terminals disrupts local protein synthesis and vesicular trafficking. The neuromuscular junction is an early site of pathology in ALS models[@kim2013][@lee2012].
Huntington's disease is characterized by early synaptic dysfunction in the striatum and cortex. Mutant huntingtin protein (mHTT) disrupts multiple aspects of synaptic vesicle cycling, including impaired vesicle transport, reduced neurotransmitter release, and altered endocytosis. mHTT interacts with synaptic including synapsin, PSD-95, and NMDA receptors, leading to complex synaptic pathology[@smith2005][@li2021].
Frontotemporal dementia (FTD) encompasses a group of disorders characterized by focal frontal and temporal lobe atrophy. Synaptic dysfunction is an early feature, with impaired neurotransmitter release and reduced synaptic protein expression. Mutations in tau (MAPT), progranulin (GRN), and C9orf72 are associated with different FTD subtypes, each showing distinct patterns of synaptic pathology[@rascovsky2011][@ferrari2014].
Dopaminergic neurons in the substantia nigra pars compacta exhibit unique synaptic properties:
These properties make dopaminergic terminals particularly vulnerable to disruptions in synaptic vesicle cycling and mitochondrial function[@surmeier2010][@bezard2013].
Basal forebrain cholinergic neurons are early victims in AD:
Cholinergic dysfunction contributes to attention and memory deficits in AD[@schliebs2011][@hampel2021].
Cerebellar Purkinje cells and granule cells show specific vulnerabilities:
Rabphilin-3A agonists: Rabphilin-3A regulates synaptic vesicle exocytosis through its interaction with Rab3A. Small molecules that enhance rabphilin-3A function may improve synaptic transmission in neurodegenerative [@bezprozvanny2005][@lin2000].
Synapsin gene therapy: Synapsin overexpression has shown protective effects in models of neurodegeneration by enhancing synaptic vesicle mobilization and reducing excitotoxicity. Adeno-associated virus (AAV)-mediated synapsin delivery is being explored for neurodegenerative disease therapy[@garciaosta2018][@zhen2014].
Botulinum neurotoxins: While typically used for muscle disorders, botulinum toxins cleave SNAP-25 and block synaptic transmission. In certain contexts, carefully titrated BoNT delivery might reduce pathological hyperexcitability, though this approach has limited applicability[@rossetto2016][@dressler2000].
Calcium channel modulators: Since calcium influx triggers neurotransmitter release, modulators of voltage-gated calcium channels can alter synaptic function. P/Q-type calcium channel blockers are used for migraine prevention and may have utility in conditions with excessive neurotransmitter release[@tottene2019][@currie2020].
V-ATPase modulators: The vacuolar-type H⁺-ATPase that acidifies synaptic vesicles is essential for neurotransmitter loading and recycling. Modulators of V-ATPase activity could enhance vesicle refilling and sustain synaptic transmission under conditions of high demand[@finley2021][@de2020].
Dynamin modulators: Small molecules that enhance dynamin function could improve synaptic vesicle endocytosis. However, given the critical role of dynamin in multiple cellular processes, specificity remains a challenge[@praefcke2004][@antonny2016].
Given the central role of α-synuclein in PD synaptic dysfunction:
Synaptic vesicle function intersects with many other cellular pathways:
| Finding | Disease | Reference |
|---|---|---|
| Aβ oligomers reduce release-ready vesicles | AD | [@shelat2009] |
| α-synuclein impairs vesicle recycling | PD | [@cheng2011] |
| TDP-43 disrupts presynaptic protein localization | ALS | [@lee2012] |
| mHTT reduces vesicle trafficking | HD | [@li2021] |
| Synapsin overexpression is neuroprotective | AD/PD | [@zhen2014] |
Synaptic vesicle trafficking and recycling represent critical points of vulnerability in neurodegenerative . The complex molecular machinery coordinating synaptic vesicle cycling involves numerous that can be disrupted by pathological characteristic of each disorder. Understanding these provides opportunities for therapeutic intervention, with approaches targeting synaptic protection, vesicle recycling enhancement, and pathological protein clearance showing promise for future treatments.